Auro Laboratories (BOM:530233) Cyclically Adjusted Revenue per Share: ₹85.79 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530233 Auro Laboratories Ltd BOM:530233
63 GF Score
Price ₹228.60
GF Value ₹261.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Auro Laboratories Cyclically Adjusted Revenue per Share?

Auro Laboratories BOM:530233 -2.91% 63 Cyclically Adjusted Revenue per Share is ₹85.79 as of Jun. 2026. GuruFocus rates BOM:530233 with a GF Score™ of 63/100 and a GF Value™ of ₹261.36 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Auro Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was ₹13.030. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹85.79 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Auro Laboratories's average Cyclically Adjusted Revenue Growth Rate was 2.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Auro Laboratories was 2.90% per year. The lowest was 0.00% per year. And the median was 0.60% per year.

As of today (2026-09-02), Auro Laboratories's current stock price is ₹228.60. Auro Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹85.79. Auro Laboratories's Cyclically Adjusted PS Ratio of today is 2.66.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Auro Laboratories was 3.43. The lowest was 0.65. And the median was 1.69.


Auro Laboratories  (BOM:530233) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Auro Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=228.60/85.79
=2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Auro Laboratories was 3.43. The lowest was 0.65. And the median was 1.69.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Auro Laboratories Cyclically Adjusted Revenue per Share Related Terms


Auro Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Auro Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Auro Laboratories Cyclically Adjusted Revenue per Share Chart

Auro Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84.15 83.96 86.86 84.04 85.42

Auro Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.97 85.43 85.29 85.42 85.79

BOM:530233 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Auro Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Auro Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Auro Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Auro Laboratories's Cyclically Adjusted PS Ratio falls into.


BOM:530233
63GF Score
Auro Laboratories Ltd BOM:530233
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Auro Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Auro Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=13.03/167.3573*167.3573
=13.030

Current CPI (Jun. 2026) = 167.3573.

Auro Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 12.879 105.961 20.341
201612 11.644 105.196 18.525
201703 16.169 105.196 25.723
201706 12.032 107.109 18.800
201709 15.639 109.021 24.007
201712 19.729 109.404 30.180
201803 17.020 109.786 25.945
201806 16.797 111.317 25.253
201809 20.117 115.142 29.240
201812 19.692 115.142 28.622
201903 16.497 118.202 23.357
201906 21.984 120.880 30.437
201909 17.824 123.175 24.217
201912 15.349 126.235 20.349
202003 13.680 124.705 18.359
202006 19.578 127.000 25.799
202009 24.656 130.118 31.712
202012 21.021 130.889 26.878
202103 19.662 131.771 24.972
202106 16.883 134.084 21.073
202109 16.516 135.847 20.347
202112 19.462 138.161 23.575
202203 28.100 138.822 33.876
202206 17.581 142.347 20.670
202209 20.239 144.661 23.414
202212 25.208 145.763 28.943
202303 20.568 146.865 23.438
202306 16.405 150.280 18.269
202309 21.534 151.492 23.789
202312 28.867 152.924 31.591
202403 17.852 153.035 19.523
202406 9.195 155.789 9.878
202409 4.937 157.882 5.233
202412 4.792 158.323 5.065
202503 11.827 157.552 12.563
202506 4.470 159.755 4.683
202509 14.198 162.289 14.641
202512 15.063 163.281 15.439
202603 15.803 164.272 16.100
202606 13.030 167.357 13.030

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹85.79 mean?
Auro Laboratories (BOM:530233) has a Cyclically Adjusted Revenue per Share of ₹85.79 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Auro Laboratories and its competitors.
Is Auro Laboratories' Cyclically Adjusted Revenue per Share too high?
Auro Laboratories' current Cyclically Adjusted Revenue per Share is ₹85.79. Overall, Auro Laboratories has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Auro Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS?
Auro Laboratories' Cyclically Adjusted Revenue per Share of ₹85.79 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Auro Laboratories and its competitors. Auro Laboratories's current Cyclically Adjusted Revenue per Share is ₹85.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Auro Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Auro Laboratories (BOM:530233) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹261.36, compared to a current price of ₹228.60 — trading 12.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹85.79. Auro Laboratories' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Auro Laboratories (BOM:530233), the current Cyclically Adjusted Revenue per Share is ₹85.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Auro Laboratories (BOM:530233) Overvalued in 2026?

Based on GuruFocus' analysis, Auro Laboratories stock appears to be undervalued. The current stock price of ₹228.60 is trading 12.5% below its estimated GF Value™ of ₹261.36. GuruFocus considers Auro Laboratories to be Modestly Undervalued.

Key valuation signals for BOM:530233:

  • Cyclically Adjusted Revenue per Share: ₹85.79
  • GF Value™: ₹261.36 vs. price of ₹228.60 (12.5% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the BOM:530233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Auro Laboratories Business Description

Address S.K. Ahire Marg, 314, 3rd Floor, T.V. Industrial Estate, Worli, Mumbai, MH, IND, 400 030
Auro Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and selling of pharmaceutical products like Metformin Hydrochloride and Glibenclamide. The pharmaceutical products range offered by the company are anti-diabetic, muscle relaxant, diuretic, iron deficiency anti-fungal, anti-ulcer, iodine supplement, anti-malaria, antacids, anti-inflammatory, specialty chemicals, and others. The company sells its products in India and also exports it to international countries.
63GF Score

Get the complete analysis for BOM:530233

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹228.60
Price
₹261.36
GF Value